Eton Pharmaceuticals launches HEMANGEOL Oral Solution for infantile hemangioma

Eton Pharmaceuticals, Inc.

HEMANGEOL is the only FDA-approved treatment for proliferating infantile hemangioma requiring systemic therapy.
Exclusively distributed through Anovo Specialty Pharmacy to streamline patient access and therapy initiation.
Eton Cares support includes $0 co-pay for eligible commercially insured patients and expanded assistance programs.
Estimated 5,000-10,000 infants treated annually in the U.S. with HEMANGEOL.
Treatment window is typically 5 weeks to 5 months of age, lasting about 6 months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.